Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Quantum BioPharma Ltd C.QNTM

Alternate Symbol(s):  QNTM

Quantum BioPharma Ltd. is a Canada-based biopharmaceutical company. The Company is engaged in building a portfolio of assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc. (Lucid), it is focused on... see more

CSE:QNTM - Post Discussion

Quantum BioPharma Ltd > Treatment of Gastro-Intestinal Diseases in Dogs and Cats
View:
Post by Jane24 on Apr 18, 2021 10:59am

Treatment of Gastro-Intestinal Diseases in Dogs and Cats

FSD Pharma also enters into License Agreement to Develop FDA approved Veterinary Drugs for the Treatment of Gastro-Intestinal Diseases in Dogs and Cats
Comment by Cuenz23 on Apr 18, 2021 11:01am
This post has been removed in accordance with Community Policy
Comment by Jane24 on Apr 18, 2021 11:01am
The licensing agreement with Innovet Italia S.R.I, to evaluate the use of ultra- micro PEA as a veterinary anti-inflammatory prescription drug, is an exciting opportunity for the company to enter into a new and untapped market
Comment by Cuenz23 on Apr 18, 2021 11:02am
This post has been removed in accordance with Community Policy
Comment by Jane24 on Apr 18, 2021 11:03am
The License Agreement provides that the Company shall develop the Licensed Products with a view to submitting an Investigational Animal Drug Application with the FDA within thirty-six (36) months of the date of the agreement and shall submit a New Animal Drug Application within sixty (60) months of the effective date of the agreement.
Comment by Mil_Man54 on Apr 18, 2021 11:04am
Pump....pump....pump.....blah....blah....blah....repeat
Comment by Jane24 on Apr 18, 2021 11:06am
LOL.
Comment by Mil_Man54 on Apr 18, 2021 11:02am
Looks like we have multi-account pumper talking to himself again....new account just created posts and older pumper account immediately responds...nothing suspicious there....LOL
Comment by Jane24 on Apr 18, 2021 11:05am
Mil_Man54  Yeah. Your talking to yourself! It also looks like a great pumper is here again.
Comment by Mil_Man54 on Apr 18, 2021 11:07am
That doesn't even make sense.....
Comment by Jane24 on Apr 18, 2021 11:09am
Mil_Man54 You have nothing to do in your life. You just keep on hating!
Comment by Jane24 on Apr 18, 2021 11:10am
Mil_Man54 PUMPER! What a mess. You are a great troublemaker.
Comment by Jane24 on Apr 18, 2021 11:11am
Comment by Mil_Man54 on Apr 18, 2021 11:12am
And you are a very bad pumper......and as long as I can make trouble for you....I'm good with that.....LOL
Comment by Mil_Man54 on Apr 18, 2021 11:11am
Sure I have lots to do....just not at this moment.....and I wouldn't say that calling out multi-account pumpers is hating.....just doing a public service
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities